Louis P. Garrison

TL;DR: It is critical that policymakers recognize the benefits, limitations, and methodological challenges in using RW data, and the need to consider carefully the costs and benefits of different forms of data collection in different situations.

TL;DR: The third section of the Special Task Force report identifies and defines a series of elements that warrant consideration in value assessments of medical technologies and aims to broaden the view of what constitutes value in health care and to spur new research on incorporating additional elements of value into cost-effectiveness analysis (CEA).

TL;DR: These schemes have the potential to alter the reimbursement and pricing landscape for medical technology, but significant challenges, including high transaction costs and insufficient information systems, may limit their long-term impact.

TL;DR: In this article, the authors provide practical recommendations for the development and application of state-of-the-art methods to be used when considering, using, or reviewing performance-based risk-sharing arrangements (PBRSAs).

TL;DR: The objective of this Task Force report was to set out the standards that should be applied to "good practices"-both research and operational-in the use of a PBRSA, encompassing questions around the desirability, design, implementation, and evaluation of such an arrangement.